Breakthrough study discovers genetic mutation could be basis for novel treatment of rheumatoid arthritis

Research reveals how a specific mutation in a protein called TRAF1 can shut down an overactive immune response, dramatically reducing inflammation in mice. This discovery could pave the way for a new class of drugs to treat rheumatoid arthritis, according to one of the authors. Using gene-editing technology, the researchers identified a critical mutation of a protein called TRAF1 and discovered that this mutation dramatically reduces inflammation by disrupting a critical molecular interaction that fuels the immune system into kicking into overdrive.